Annexon, Inc. (“Annexon”) announced the pricing of its underwritten public offering of 25,096,153 shares of common stock at $2.60 per share, with expected gross proceeds of $75 million. The offering is set to close on November 14, 2025, with an option for underwriters to purchase an additional 4,326,922 shares. Goldman Sachs & Co. LLC, TD Cowen, and Wells Fargo Securities are acting as joint book-running managers. Annexon aims to develop complement inhibitors targeting neuroinflammation for various diseases, with a mission to provide innovative therapies to patients globally.

Read more at GlobeNewswire: Annexon Announces Pricing of $75 Million Public Offering of